Drug-Resistant Superbugs, Multi-drug Resistant Organisms: MRSA, VRE, Clostridium difficile, and CRE (by LabCE)

2.5 P.A.C.E. contact hour(s)

(based on 1,155 customer ratings)

Authors: Carolyn M. Law, PhD, MT(AMT); Catherine Dragoni, MT(ASCP)SM
Co-author: Judi Bennett, MT, BSM
Reviewer: Alexandru Casapu, MBA, MLS(ASCP)CM

Course provided by LabCE.

In light of the recent death of a Nevada woman infected with carbapenem-resistant Enterobacteriaceae (CRE), we wonder how prepared our laboratory professionals are for the challenges that may lie ahead.
To aid in the continued education about CRE and other multi-drug resistant microbes, we're republishing our Multi-drug Resistant Organisms: MRSA, VRE, Clostridium difficile, and CRE course. New information and updates have been added to address the potential of increased CRE infections.
Multiple drug resistant organisms (MDROs) are a serious problem facing healthcare and the general public. This course details the clinical significance, risk factors, and laboratory detection of these multi-drug resistant organisms: methicillin resistant Staphylococcus aureus, vancomycin resistant Enterococcus species, Clostridium difficile, and carbapenem-resistant Enterobacteriaceae.

See more courses in: Microbiology

Included In These Course Packages

Continuing Education Credits

P.A.C.E.® Contact Hours (acceptable for AMT, ASCP, and state recertification): 2.5 hour(s)
Course number 578-074-20, approved through 8/31/2022
Florida Board of Clinical Laboratory Personnel Credit Hours - General (Microbiology/Mycology/Parasitology): 2.5 hour(s)
Course number 20-786048, approved through 9/1/2020

Objectives

  • Identify the virulence factors that are expressed by drug resistant strains of Staphylococcus aureus, Clostridium difficile, Enterococcus faecium and faecalis, and carbapenem-resistant Enterobacteriaceae.
  • List the risk factors and clinical syndromes that are associated with these drug resistant organisms.
  • Describe the recommended laboratory procedures involved in screening for and detecting drug-resistant organisms.
  • Name the drugs that are currently available for treatment of these infections and describe the proper treatment protocols.

Customer Ratings

(based on 1,155 customer ratings)

Course Outline

  • Introduction
      • Methicillin Resistant Staphylococcus aureus
      • Vancomycin Resistant Enterococci
      • Clostridium difficile
      • Carbapenem-Resistant Enterobacteriaceae
  • Staphylococcus aureus
      • Staphylococcus aureus
      • S. aureus Virulence Factors
      • Clinical significance of S. aureus
      • Beta-lactam antibiotics and S. aureus
  • MRSA
      • Beta-lactams and Methicillin Resistant Staphylococcus aureus
      • Healthcare (Hospital)-Associated MRSA (HA-MRSA) versus Community-Associated MRSA (CA-MRSA)
      • Risk Factors
  • Laboratory Diagnosis of MRSA
      • Laboratory Identification of S. aureus
      • Screening Cultures for MRSA
    • Susceptibility Testing of Isolates
      • Susceptibility Testing
      • Selection of Drugs for Testing
      • Interpretation of Oxacillin Broth Dilution Tests.
      • Interpretation of Oxacillin and Cefoxitin Disk Diffusion Tests
      • Detection of Oxacillin Resistance
  • MRSA Treatment/Vancomycin Resistance in S. aureus
      • MRSA Treatment/Vancomycin Resistance
      • Vancomycin-Intermediate S. aureus (VISA) and Vancomycin-Resistant S. aureus (VRSA)
    • Testing for Vancomycin Susceptibility
      • Testing for Vancomycin Susceptibility
  • Future Perspectives: MRSA
      • Future Perspectives
      • Future Perspectives, continued
      • Future Perspectives, continued
  • Enterococcus
      • Enterococci
      • Risk Factors and Resistance
  • Vancomycin Resistant Enterococci
      • Vancomycin-Resistant Enterococci (VRE) Phenotypes
  • Laboratory Diagnosis of VRE
      • Identification of Enterococcus Species From Clinical Cultures
      • Screening Cultures for Vancomycin-Resistant Enterococci (VRE)
      • Susceptibility Testing of Enterococci
      • Detecting Vancomycin Resistance
      • High Level Aminoglycoside Resistance (HLAR) Screening
  • Treatment of Resistant Enterococci
      • Newer antibiotics for Treatment of Resistant Enterococci
  • Clostridium Species
      • Clostridium Species
  • Clostridium difficile
      • Clostridium difficile
      • C. difficile Toxin A and Toxin B
      • Pathogenisis of C. Difficile-Associated Diarrhea
      • Risk factors for C. difficile Infection
      • C. difficile-associated Diarrhea (CDAD)
      • Strain BI/NAP1/027
  • Laboratory Diagnosis of CDAD
      • Laboratory Detection of C. difficile
      • Stool Culture
      • Cell Cytotoxicity Neutralization Assay (CCNA)
      • Enzyme Immunoassay Methods
      • Glutamate Dehydrogenase (GDH) Antigen Assays
      • Molecular Methods
  • Treatment of C. difficile Infection
      • Treatment of C. difficile Infection (CDI) and C. difficile Associated Disease (CDAD)
      • Disinfection & Control of C. difficile Infection
  • Future perspectives
      • Future Perspectives: CDI/CDAD
  • Carbapenem-Resistant Enterobacteriaceae
      • Enterobacteriaceae and Spectrum of Disease
      • CRE Defined and Risk Factors
      • Mechanisms of Resistance
      • Carbapenemase-Producing Enterobacteriaceae
  • Laboratory Diagnosis of CRE
      • Detection, Identification, and Susceptibility Testing of CRE
      • Summary: CRE Versus CP-CRE
  • Treatment and Control of CRE
      • Treatment of CRE
      • Control of CRE
      • CRE Screening
  • Future Perspective: CRE
      • Future Perspecitves: CRE
  • References
      • References

Additional Information

Level of instruction: Intermediate
 
Intended audience: Medical laboratory scientists, medical technologists, and technicians, This course is also appropriate for clinical laboratory science students and pathology residents.
 
Author information: Carolyn M. Law, PhD, MT(AMT) is the CEO of Celtic Labs Diagnostic Microbiology Services in Trinidad. She holds a PhD in Microbiology from National University of Ireland, Maynooth.
 
Author information: Catherine Dragoni, MT(ASCP)SM received her BS degree in medical technology fr
om the State University of New York, Upstate Medical Center, Syracuse. She began her career as a bench microbiologist at Maine Medical Center, Portland, Maine. Currently she is the Assistant Chief Technologist of Microbiology and Molecular Pathology at NorDx Laboratories, Scarborough, Maine.
 
Co-author information: Judi Bennett, MT, BSM is currently a Program Director for MediaLab, Inc. in Lawrenceville, Georgia. She has over 30 years of medical laboratory experience in an acute care hospital setting as a laboratory manager, senior clinical applications specialist, point-of-care coordinator, microbiology supervisor, and generalist technologist. Judi has experience speaking at various professional conferences and is the author of numerous peer-reviewed publications.  
 
Reviewer Information: Alexandru Casapu, MBA, MLS(ASCP)CM, PBTCM has over 20 years of experience as a medical laboratory scientist, section supervisor, and laboratory manager. He is the former Director of Clinical Laboratory Technology Program at Georgia Piedmont Technical College. He is currently a Program Director at MediaLab, Inc. Alexandru holds BS degrees in Biology and Medical Technology from Clark Atlanta University and a MBA from the University of Georgia.

How to Subscribe
MLS & MLT Comprehensive CE Package (by LabCE)
Package of 122 online courses$95
Add to cart
Single online course$20
Add to cart
  • Order for instant access through any computer, any browser.
  • No shipping, faxing, or waiting for certificates.
  • Print or save your certificate of completion as soon as you've completed the course.
  • You'll have 90 days to complete your purchased courses.
Course provided by LabCE.
C diff on BAP_edit


C diff_gram


C. diff on CCFA_edit


Staph



 
ASCLS CE's design and platform are provided by MediaLab, Inc.